Spark’s Corrective Gene Therapy Could Be First to Cost $1 Million – Atlantic Information Services, Inc.
pharmaphorum |
Spark's Corrective Gene Therapy Could Be First to Cost $1 Million
Atlantic Information Services, Inc. If the FDA follows an advisory committee's lead, the agency will approve a gene therapy that treats a rare form of blindness by early next year. Spark Therapeutics Inc.'s Luxturna (voretigene neparvovec) would be the first gene therapy in the United … Out of the darkness: new gene therapies for eye diseases |
